AGROAMERICA
5.9.2020 03:28:08 CEST | Business Wire | Press release
AgroAmerica, a globally recognized sustainable company, has been invited since 2017 to sponsor the Central American Donors Forum , an initiative of the Seattle International Foundation (SIF), to generate alliances and advance in development efforts in Central America to generate a greater social impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200904005525/en/
The Forum has the participation of over 400 leaders from business, government, private sector, media outlets, and civil society, as well as international and regional panelists, to discuss priority issues and promote Social Responsibility. For the first time since its inception, the 2020 Forum was held virtually and was open to all audiences.
From September 1 - 3, 2020, the interventions of the different Forum participants focused on the “Reinvention and resistance in times of crisis” . The COVID-19 pandemic has exposed many of the vulnerabilities and concerns of Central America based on the construction of alternative responses to the economic impact, gender approach, migration, and the role of companies to increase market access for all.
Promoting development:
For the 4th consecutive year, AgroAmerica participated as a sponsor of the Forum, promoting the development of the Central American region and the implementation of good business, labor, social and environmental practices.
During 2019, the Forum's central theme was “Progress at the Crossroads”. More than 30 conferences, panels, and workshops were held in Tegucigalpa, Honduras, addressing Economic Development, Youth, Feminist Movements, Corruption, Migration, Human Rights, Democracy, Public-Private Partnerships, among others.
In 2018, the forum was held in San Salvador, El Salvador, developing the theme “Creating space for everyone”, highlighting the role of corporate social responsibility in building a more inclusive region through strategic alliances with social actors.
In 2017, AgroAmerica CEO, Fernando Bolaños, was a member of the host committee, as well as a panelist of the Forum that revolved around the theme “Reimagining Partnerships” held in Panama City.
Bolaños participated on the panel Social Responsibility: The Role of Influential People in the Construction of Democracy in Central America . “There are many challenges facing Central America,” said Bolaños during his intervention. “Our challenges are all connected and linked – food security, poverty, gender equality, health and education to name just a few. At AgroAmerica we strive to create a sustainable development initiative through partnerships, so we can improve the lives of our employees and the people in the surrounding communities.”
AgroAmerica will continue contributing to initiatives that promote a more inclusive region through its Corporate Sustainability Strategy and strategic alliances with social actors.
About AgroAmerica:
AgroAmerica is an agroindustrial corporation dedicated the production and commercialization of food products, using sustainable and responsible farming methods. With operations in Europe, United States, México, Guatemala, Ecuador, Perú, and Panamá. AgroAmerica operates based on a Corporate Sustainability strategy to generate value and balance among economic growth, natural resource conservation, and our customers and stakeholders wellbeing. Visit us: https://agroamerica.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005525/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
